Cisterna Biologics

About Cisterna Biologics

Cisterna Biologics develops high-purity mRNA using its proprietary SPEcific Capture and Cleavage (SPECC) technology, which eliminates product-related impurities that can compromise therapeutic efficacy. The company addresses the challenges of quality, quantity, and cost in mRNA production, enabling more effective applications in gene editing and protein replacement therapies.

```xml <problem> Current mRNA production methods struggle to eliminate product-related impurities such as double-stranded RNA (dsRNA), long RNA impurities (LRNA), and short truncated RNA (stRNA). These impurities can increase immunogenicity and compromise the efficacy of mRNA in applications like CRISPR gene editing and protein replacement therapies. </problem> <solution> Cisterna Biologics utilizes its proprietary SPEcific Capture and Cleavage (SPECC) technology to produce high-purity mRNA, eliminating product-related impurities without the need for HPLC purification. This advanced platform leverages cutting-edge chemistry and ribozymes to create mRNA molecules of unparalleled purity, addressing the challenges of quality, quantity, cost, and delivery lead time in mRNA production. By providing exceptionally high-quality mRNA, Cisterna Biologics enables more effective applications in gene editing, protein replacement therapies, and other advanced biotechnological solutions employing mRNA. </solution> <features> - SPECC technology: A proprietary process for producing mRNA of unparalleled purity. - Eliminates product-related impurities: Removes dsRNA, LRNA, and stRNA without HPLC purification. - Cutting-edge chemistry and ribozymes: Leverages advanced techniques for mRNA molecule creation. - High-quality mRNA: Ensures increased efficacy and reduced immunogenicity in therapeutic applications. - dT-purified and SPECC-purified mRNA: Available to qualified customers on a research use only (RUO) basis. </features> <target_audience> The primary customers are researchers and companies in the biotechnology and pharmaceutical industries focused on mRNA-based therapeutics, gene editing, and protein replacement therapies. </target_audience> ```

What does Cisterna Biologics do?

Cisterna Biologics develops high-purity mRNA using its proprietary SPEcific Capture and Cleavage (SPECC) technology, which eliminates product-related impurities that can compromise therapeutic efficacy. The company addresses the challenges of quality, quantity, and cost in mRNA production, enabling more effective applications in gene editing and protein replacement therapies.

Where is Cisterna Biologics located?

Cisterna Biologics is based in Carlsbad, United States.

When was Cisterna Biologics founded?

Cisterna Biologics was founded in 2022.

How much funding has Cisterna Biologics raised?

Cisterna Biologics has raised 500000.

Who founded Cisterna Biologics?

Cisterna Biologics was founded by Jon Armstrong.

  • Jon Armstrong - Founder
Location
Carlsbad, United States
Founded
2022
Funding
500000
Employees
2 employees
Major Investors
Y Combinator
Looking for specific startups?
Try our free semantic startup search

Cisterna Biologics

Score: 100/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

Cisterna Biologics develops high-purity mRNA using its proprietary SPEcific Capture and Cleavage (SPECC) technology, which eliminates product-related impurities that can compromise therapeutic efficacy. The company addresses the challenges of quality, quantity, and cost in mRNA production, enabling more effective applications in gene editing and protein replacement therapies.

cisternabx.com300+
cb
Crunchbase
Founded 2022 – Carlsbad, United States

Funding

$

Estimated Funding

$500K+

Major Investors

Y Combinator

Team (<5)

Jon Armstrong

Founder

Company Description

Problem

Current mRNA production methods struggle to eliminate product-related impurities such as double-stranded RNA (dsRNA), long RNA impurities (LRNA), and short truncated RNA (stRNA). These impurities can increase immunogenicity and compromise the efficacy of mRNA in applications like CRISPR gene editing and protein replacement therapies.

Solution

Cisterna Biologics utilizes its proprietary SPEcific Capture and Cleavage (SPECC) technology to produce high-purity mRNA, eliminating product-related impurities without the need for HPLC purification. This advanced platform leverages cutting-edge chemistry and ribozymes to create mRNA molecules of unparalleled purity, addressing the challenges of quality, quantity, cost, and delivery lead time in mRNA production. By providing exceptionally high-quality mRNA, Cisterna Biologics enables more effective applications in gene editing, protein replacement therapies, and other advanced biotechnological solutions employing mRNA.

Features

SPECC technology: A proprietary process for producing mRNA of unparalleled purity.

Eliminates product-related impurities: Removes dsRNA, LRNA, and stRNA without HPLC purification.

Cutting-edge chemistry and ribozymes: Leverages advanced techniques for mRNA molecule creation.

High-quality mRNA: Ensures increased efficacy and reduced immunogenicity in therapeutic applications.

dT-purified and SPECC-purified mRNA: Available to qualified customers on a research use only (RUO) basis.

Target Audience

The primary customers are researchers and companies in the biotechnology and pharmaceutical industries focused on mRNA-based therapeutics, gene editing, and protein replacement therapies.